These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 44041)

  • 1. [Serum creatine kinase in patients treated with depot neuroleptics. A pilot study].
    Bjørndal F; Lauritsen B; Lyngbye J; Waarst S
    Ugeskr Laeger; 1979 Dec; 141(51):3514-6. PubMed ID: 44041
    [No Abstract]   [Full Text] [Related]  

  • 2. Risperidone-induced marked elevation of serum creatine kinase in adolescence. A case report.
    Holtmann M; Meyer AE; Pitzer M; Schmidt MH
    Pharmacopsychiatry; 2003 Nov; 36(6):317-8. PubMed ID: 14663658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Retrospective comparative study of treatment with delayed-action neuroleptics and neuroleptics administrated orally in long-term psychosis].
    Chambon O; Marie-Cardine M; Terra JL; Corot P
    Encephale; 1988; 14(4):293-7. PubMed ID: 2904356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antipsychotic drugs with long lasting effect. Depot neuroleptics].
    Kristjansen P
    Ugeskr Laeger; 1980 Mar; 142(10):657-60. PubMed ID: 6102811
    [No Abstract]   [Full Text] [Related]  

  • 5. [Psychosis treated with neuroleptics. Myositis and rise in serum creatine kinase during acute episodes].
    Luaute JP; Zampa P; Forray JP; Brochier C; Carrier H; Guidollet J
    Nouv Presse Med; 1981 Sep; 10(33):2751. PubMed ID: 6117053
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antipsychotics and rhabdomyolysis. Differential diagnosis and clinical significance of elevated serum creatine kinase levels in psychiatric practice].
    Vörös V; Osváth P; Fekete S; Tényi T
    Psychiatr Hung; 2009; 24(3):175-84. PubMed ID: 19794225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects and side effects of depot neuroleptics as perceived by patients].
    Trenckmann U
    Psychiatr Prax; 1990 Sep; 17(5):184-7. PubMed ID: 1980015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does electroconvulsive therapy exacerbate the elevation of creatinine phosphokinase caused by neuroleptics.
    Geizer M; Ancill R
    Can J Psychiatry; 1996 Mar; 41(2):131. PubMed ID: 8705961
    [No Abstract]   [Full Text] [Related]  

  • 9. The attitude of patients towards antipsychotic depot treatment.
    Heres S; Schmitz FS; Leucht S; Pajonk FG
    Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Depot neuroleptics in social psychiatric practice].
    Pruss U; Rose HK; Zechner A
    Psychiatr Prax; 1984 Jul; 11(4):101-8. PubMed ID: 6148764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depot neuroleptic therapy: an underutilized treatment option.
    Glazer WM; Kane JM
    J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyolysis complicating rapid intramuscular neuroleptization.
    Thase ME; Shostak M
    J Clin Psychopharmacol; 1984 Feb; 4(1):46-8. PubMed ID: 6141190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
    Möller HJ; Kissling W
    Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmaceutical characteristics of depot neuroleptics. Their use and efficacy in the psychiatric clinic].
    Mungiu OC; Chiriţă V; Boişteanu P; Mungiu A; Cosmovici N; Pirozynski T
    Rev Med Chir Soc Med Nat Iasi; 1988; 92(1):43-7. PubMed ID: 2899341
    [No Abstract]   [Full Text] [Related]  

  • 16. Social aspects of therapy with depot neuroleptics in the Federal Republic of Germany.
    Haring C; Tegeler J; Lehmann E; Ptock WD
    Acta Psychiatr Belg; 1981; 81(2):189-202. PubMed ID: 6117189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experiences with depot-neuroleptics in an after-care unit. Organization of the therapy exemplified with pipotiazine palmitate].
    Salvesen C; Vaksdal K
    Tidsskr Nor Laegeforen; 1973 Aug; 93(24):1699-703. PubMed ID: 4149082
    [No Abstract]   [Full Text] [Related]  

  • 18. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depot neuroleptics: side effects and safety.
    Marder SR
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.